Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24611286 | 0.92 | PIK3CD (0.33) | MGLLLMNA | |
| SCHEMBL17430432 | 0.87 | MGLL (0.36) | MGLLGLAKMT2AATMMEN1 | |
| SCHEMBL18915837 | 0.87 | MGLL (0.32) | MGLLGLA | |
| SCHEMBL14450855 | 0.87 | GLA (0.30) | GLA | |
| SCHEMBL13551294 | 0.85 | MGLL (0.35) | MGLLGLAKMT2AATM | |
| SCHEMBL18908274 | 0.85 | MGLL (0.35) | MGLLGLAKMT2AATM | |
| SCHEMBL20292599 | 0.84 | MGLL (0.33) | MGLLGLAKMT2AMEN1LMNA | |
| SCHEMBL22954473 | 0.83 | MGLL (0.34) | MGLLKMT2AATM | |
| SCHEMBL13061953 | 0.83 | MGLL (0.34) | MGLLKMT2AATM | |
| SCHEMBL18540883 | 0.83 | MGLL (0.34) | MGLLKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1001 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689898-B1 | LONG-ACTING CONJUGATE OF GLUCAGON-LIKE PEPTIDE-2 (GLP-2) DERIVATIVE | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-29 | — | — | EP | claimed |
| US-12508298-B2 | Protein complex by use of a specific site of an immunoglobulin fragment for linkage | HANMI PHARM. CO., LTD. (KR) | 2025-12-30 | — | — | US | claimed |
| EP-4534107-A2 | PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE | Hanmi Pharm. Co., Ltd. (KR) | 2025-04-09 | — | — | EP | claimed |
| US-20230090790-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2023-03-23 | — | — | US | claimed |
| CN-108136276-B | Protein complexes linked by using specific sites of immunoglobulin fragments | 韩美药品株式会社 | 2023-02-28 | — | — | CN | claimed |
| US-20230027238-A1 | METHODS OF TREATMENT USING G-CSF PROTEIN COMPLEX | SPECTRUM PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | claimed |
| EP-4069724-A1 | METHODS OF TREATMENT USING G-CSF PROTEIN COMPLEX | Spectrum Pharmaceuticals, Inc. (US) | 2022-10-12 | — | — | EP | claimed |
| US-20220251164-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2022-08-11 | — | — | US | claimed |
| US-20220249615-A1 | PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE | HANMI PHARM. CO., LTD (KR) | 2022-08-11 | — | — | US | claimed |
| US-11389508-B2 | Protein complex by use of a specific site of an immunoglobulin fragment for linkage | HANMI PHARM. CO., LTD. (KR) | 2022-07-19 | — | — | US | claimed |
| CN-108884455-A | Therapeutic enzyme conjugate assemblies | 韩美药品株式会社 | 2018-11-23 | — | — | CN | claimed |
| US-20180326013-A1 | PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE | HANMI PHARM. CO., LTD (KR) | 2018-11-15 | — | — | US | claimed |
| EP-3341025-A1 | PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE | Hanmi Pharm. Co., Ltd. (KR) | 2018-07-04 | — | — | EP | claimed |
| WO-2017052329-A1 | PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE | HANMI PHARM. CO., LTD. (KR) | 2017-03-30 | — | — | WO | claimed |
| US-8445612-B2 | Conjugation reactions | BIOCOMPATIBLES UK LIMITED (GB) | 2013-05-21 | — | — | US | claimed |
| US-20120016082-A1 | CONJUGATION REACTIONS | BIOCOMPATIBLES UK LIMITED (GB) | 2012-01-19 | — | — | US | claimed |
| EP-1592719-B1 | CONJUGATION REACTIONS | BIOCOMPATIBLES UK LTD (GB) | 2008-03-26 | — | — | EP | claimed |
| US-20060135714-A1 | Conjugation reactions | BIOCOMPATIBLES UK LIMITED (GB) | 2006-06-22 | — | — | US | claimed |
| EP-1592719-A1 | CONJUGATION REACTIONS | Biocompatibles UK Limited (GB) | 2005-11-09 | — | — | EP | claimed |
| WO-2004063237-A1 | CONJUGATION REACTIONS | BIOCOMPATIBLES UK LIMITED (GB) | 2004-07-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016082-A1 | CONJUGATION REACTIONS | PHPT1, GNE, MGMT | MGLL 4388/4885GLA 3819/4885KMT2A 900/4885 |
| US-20230090790-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | GIPR, VIP, GLP1R | MGLL 436/4885GLA 343/4885KMT2A 2059/4885 |
| US-20220251164-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | GLP1R, GIPR, IAPP | MGLL 444/4885GLA 636/4885KMT2A 1649/4885 |
| US-12508298-B2 | Protein complex by use of a specific site of an immunoglobulin fragment for linkage | FCGR3B, FCGR2A, FCER2 | MGLL 3042/4885GLA 3249/4885KMT2A 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.